Share on Facebook
Share on Twitter
Share on LinkedIn
Share by Email
Print
Mylan announced the launch of Mycophenolic Acid Delayed-Release Tablets, the generic version of Novartis‘ Myfortic.
RELATED: Immune Disorders Resource Center
Mycophenolic Acid is an immunosuppressant indicated for the prophylaxis of organ rejection in adults receiving kidney transplant, and for the prophylaxis of organ rejection in pediatric patients >5 years who are at least 6 months post kidney transplant.
Mycophenolic Acid exhibits a cytostatic effect on T- and B-lymphocytes by inhibiting inosine monophosphate dehydrogenase (IMPDH). Blocking this pathway inhibits de novo guanosine nucleotide synthesis, therefore suppressing T- and B-lymphocyte proliferation.
Mylan’s Mycophenolic Acid Delayed-Release Tablets are available in 180mg and 360mg dosage strengths.
For more information call (800) RX-MYLAN or visit Mylan.com.
